Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity.
Adoptive transfer of antigen-specific T cells is a compelling tool to treat cancer. To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antigens, robust systems for the genetic modification and characterization of T cells expressing chimeric antigen receptors (CARs) to redirect specificity have been produced. Refinements with regards to persistence and trafficking of the genetically modified T cells are underway to help improve the potency of genetically modified T cells. Clinical trials utilizing this technology demonstrate feasibility, and increasingly, antitumor activity, paving the way for multi-center trials to establish the efficacy of this novel T-cell therapy.
Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. pkebriae@mdanderson.org
Partow
P
Kebriaei
Susan S
SS
Kelly
Pallavi
P
Manuri
Bipulendu
B
Jena
Rineka
R
Jackson
Elizabeth
E
Shpall
Richard
R
Champlin
Laurence J N
LJ
Cooper
D000951:Antigens, Neoplasm / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D016219:Immunotherapy, Adoptive; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D011946:Receptors, Antigen / Q000276:immunology*; D037182:T-Cell Antigen Receptor Specificity / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
D000951:Antigens, Neoplasm; D011946:Receptors, Antigen